Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”

Detalles Bibliográficos
Autores principales: Trumbo, Henry, Kaluza, Karolina, Numan, Syed, Goodnough, Lawrence T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053176/
https://www.ncbi.nlm.nih.gov/pubmed/33835350
http://dx.doi.org/10.1007/s40264-021-01059-x
_version_ 1783680069088051200
author Trumbo, Henry
Kaluza, Karolina
Numan, Syed
Goodnough, Lawrence T.
author_facet Trumbo, Henry
Kaluza, Karolina
Numan, Syed
Goodnough, Lawrence T.
author_sort Trumbo, Henry
collection PubMed
description
format Online
Article
Text
id pubmed-8053176
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80531762021-05-05 Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System” Trumbo, Henry Kaluza, Karolina Numan, Syed Goodnough, Lawrence T. Drug Saf Letter to the Editor Springer International Publishing 2021-04-09 2021 /pmc/articles/PMC8053176/ /pubmed/33835350 http://dx.doi.org/10.1007/s40264-021-01059-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter to the Editor
Trumbo, Henry
Kaluza, Karolina
Numan, Syed
Goodnough, Lawrence T.
Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title_full Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title_fullStr Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title_full_unstemmed Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title_short Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
title_sort authors’ reply to michael auerbach’s comment on: “frequency and associated costs of anaphylaxis- and hypersensitivity-related adverse events for intravenous iron products in the usa: an analysis using the us food and drug administration adverse event reporting system”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053176/
https://www.ncbi.nlm.nih.gov/pubmed/33835350
http://dx.doi.org/10.1007/s40264-021-01059-x
work_keys_str_mv AT trumbohenry authorsreplytomichaelauerbachscommentonfrequencyandassociatedcostsofanaphylaxisandhypersensitivityrelatedadverseeventsforintravenousironproductsintheusaananalysisusingtheusfoodanddrugadministrationadverseeventreportingsystem
AT kaluzakarolina authorsreplytomichaelauerbachscommentonfrequencyandassociatedcostsofanaphylaxisandhypersensitivityrelatedadverseeventsforintravenousironproductsintheusaananalysisusingtheusfoodanddrugadministrationadverseeventreportingsystem
AT numansyed authorsreplytomichaelauerbachscommentonfrequencyandassociatedcostsofanaphylaxisandhypersensitivityrelatedadverseeventsforintravenousironproductsintheusaananalysisusingtheusfoodanddrugadministrationadverseeventreportingsystem
AT goodnoughlawrencet authorsreplytomichaelauerbachscommentonfrequencyandassociatedcostsofanaphylaxisandhypersensitivityrelatedadverseeventsforintravenousironproductsintheusaananalysisusingtheusfoodanddrugadministrationadverseeventreportingsystem

Ejemplares similares